However, similarly to what was discussed on galectin-1, it is unlikely that tumor-derived circulating galectin-3 reaches the concentrations required to reveal its pro-apoptotic properties in the tumor-draining lymph nodes in cancer patients. Here, LGALS1 is linked to cancer.